UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results
Tweet Send to a Friend
UBS analyst Priya Sachdeva reiterated a Buy rating and $18.00 price target on NeuroPace Inc (NASDAQ: NPCE).The analyst commented, "NPCE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
